Showing results (871-880 of 1,598) with videos related to
Sort By:
Pageof 160
Cancer Journal (Sudbury, Mass.)|September 27, 2021
Precision Radiotherapy for Gliomas: Implementing Novel Imaging Biomarkers to Improve Outcomes With Patient-Specific TherapyMichael Connor, Michelle M Kim, Yue Cao, et al.Cancer Journal (Sudbury, Mass.)|May 29, 2019
T-Cell Receptor-Based Immunotherapy for Hematologic MalignanciesMelinda A Biernacki, Michelle Brault, Marie BleakleyCancer Journal (Sudbury, Mass.)|March 25, 2022
Lessons From the Impact of the COVID-19 Pandemic at the National Cancer Institute: Cancer Research and CareFatima Karzai, William L DahutCancer Journal (Sudbury, Mass.)|March 25, 2022
Telemedicine Across the Cancer Care Continuum: Evidence and Opportunities for Clinical Care, Research, and PolicyLarissa Nekhlyudov, Lee A Fleisher, Paul B JacobsenCancer Journal (Sudbury, Mass.)|January 24, 2022
Incorporation of FLT3 Inhibitors Into the Treatment Regimens for FLT3 Mutated Acute Myeloid Leukemia: The Case for Total TherapyAlexander E Perl, Keith W PratzCancer Journal (Sudbury, Mass.)|January 24, 2022
The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old DrugsNicholas J Short, Hervé Dombret, Lionel Adès, et al.Cancer Journal (Sudbury, Mass.)|January 24, 2022
Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid LeukemiaFadi Haddad, Amer M Zeidan, Naval DaverCancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S HouriganCancer Journal (Sudbury, Mass.)|January 24, 2022
The Evolving Role of Allogeneic Stem Cell Transplant in the Era of Molecularly Targeted AgentsFrancesca Kinsella, Charles CraddockCancer Journal (Sudbury, Mass.)|September 22, 2021
Monoclonal Antibodies in Myeloma: Optimizing Targeted TherapyMonique Hartley-Brown, David Chitty, Richa ThakurPageof 160